Download PDF
Kardiologie up2date 2010; 6(3): 257-272
DOI: 10.1055/s-0030-1255671
Thrombozyten und Gerinnungssystem bei kardiovaskulären Erkrankungen

© Georg Thieme Verlag KG Stuttgart · New York

Antikoagulation bei Vorhofflimmern

Tobias  Geisler, Marcus  Flather
Further Information

Publication History

Publication Date:
21 September 2010 (online)

Also available at
    Permissions and Reprints All articles of this category

Abstract

Atrial fibrillation (AF) is characterized by insufficient coordination of atrial activity leading to a loss of effective atrial contraction. AF can lead to different clinical conditions, including cerebrovascular and systemic thromboembolism, decompensated heart failure, and/or oligosymptomatic and symptomatic tachycardias. A global therapeutic approach should target these issues, and encompass conversion of maintenance of rhythm by means of electric cardioversion and drug and/or interventional therapies and effective anticoagulation to prevent thromboembolism in certain risk groups. The risk for stroke increases depending on patient age and comorbidities. Therapeutic goal consists of safeguarding of effective anticoagulation under tolerable bleeding risk. This poses a growing challenge in the light of complex cases and individual risk factors, as well as the development of new antithrombotics. Treatment with vitamin K antagonists demands a complicated patient management, is difficult to handle and susceptible for drug interactions, nutritional influences and genetic polymorphisms. The aim of the subsequent article is to give a current overview over treatment strategies for prophylaxis of thromboembolism in patients with AF considering present treatments and recent development focussing on novel thrombin inhibitors.

Kernaussagen

  • Komplikationen des Vorhofflimmerns sind zerebrovaskuläre Embolien, dekompensierte Herzinsuffizienz, Ischämien oder oligosymptomatische und symptomatische Tachykardien. Das Schlaganfallrisiko bei Patienten mit Vorhofflimmern hängt von begleitenden Risikofaktoren ab und steigt mit dem Alter an.

  • Zur Vorbeugung von Thromboembolien ist bei bestimmten Risikogruppen eine effektive antikoagulatorische Behandlung wichtig. Die Indikation zur oralen Antikoagulation sollte man dabei anhand des individuellen Risikoprofils stellen.

  • Eine besondere Risikogruppe für thrombotische Komplikationen sind Patienten mit Vorhofflimmern und symptomatischer KHK. Bei ihnen sollte man eine Kombination von oralen Antikoagulanzien und antithrombozytären Substanzen nach sorgfältiger Abschätzung des Blutungsrisikos in Erwägung ziehen.

  • Vitamin-K-Antagonisten senken das Schlaganfallrisiko erheblich, ihre variable Wirksamkeit ist jedoch ein ernstes Problem. Sie erfordern eine komplizierte Patientenführung, sind schwierig zu steuern und anfällig für medikamentöse Wechselwirkungen, nutritive Einflüsse und genetische Polymorphismen.

  • Neue orale Antikoagulanzien (direkte Thrombininhibitoren und Faktor-Xa-Antagonisten) sind derzeit in Phase-III-Studien zur Thrombembolieprophylaxe bei Vorhofflimmern in Erprobung. Bislang sind die Ergebnisse bezüglich ihrer Effektivität und Sicherheit im Vergleich zu den Vitamin-K-Antagonisten vielversprechend.

Literatur

  • 1 Stroke Risk in Atrial Fibrillation Working Group . Independent predictors of stroke in patients with atrial fibrillation: a systematic review.  Neurology. 2007;  69 546-554
    CrossrefPubMedGoogle Scholar
  • 2 Stroke Risk in Atrial Fibrillation Working Group . Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation.  Stroke. 2008;  39 1902-1910
    PubMedGoogle Scholar
  • 3 Atrial Fibrillation Investigators . Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials.  Arch Intern Med. 1994;  154 1449-1457
    CrossrefPubMedGoogle Scholar
  • 4 Gage B F, van Walraven C, Pearce L. et al . Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.  Circulation. 2004;  110 2287-2292
    CrossrefPubMedGoogle Scholar
  • 5 Wang T J, Massaro J M, Levy D. et al . A risk score for predicting stroke or death in indiciduals with new-onset atrial fibrillation in the community: the Framingham Heart Study.  JAMA. 2003;  290 1049-1056
    CrossrefPubMedGoogle Scholar
  • 6 Singer D E, Albers G W, Dalen J E. et al . Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).  Chest. 2008;  133 546-592
    CrossrefPubMedGoogle Scholar
  • 7 Nieuwlaat R, Capucci A, Lip G Y. et al . Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation.  Eur Heart J. 2006;  27 3018-3026
    CrossrefPubMedGoogle Scholar
  • 8 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators . The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.  N Engl J Med. 1990;  323 1505-1511
    CrossrefPubMedGoogle Scholar
  • 9 National Collaborating Centre for Chronic Conditions .Atrial Fibrillation: national clinical guideline for management in primary and secondary care. London; Royal College of Physicians 2006 http://rcplondon.ac.uk/pubs/books/af/index.asp ; Stand: 2006
    PubMedGoogle Scholar
  • 10 Fuster V, Ryden L E, Cannom D S. et al . ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation.  Europace. 2006;  8 651-745
    CrossrefPubMedGoogle Scholar
  • 11 Hart R G, Pearce L A, Agullar M I. Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation: a meta-analysis.  Ann Intern Med. 2007;  146 857-867
    CrossrefPubMedGoogle Scholar
  • 12 Petersen P, Boysen G, Godtfredsen J. et al . Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.  Lancet. 1989;  1 175-179
    PubMedGoogle Scholar
  • 13 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators . The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.  N Engl J Med. 1990;  323 1505-1511
    CrossrefPubMedGoogle Scholar
  • 14 Connolly S J, Laupacis A, Gent M. et al . Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.  J Am Coll Cardiol. 1991;  18 349-355
    CrossrefPubMedGoogle Scholar
  • 15 EAFT (European Atrial Fibrillation Trial) Study Group . Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke.  Lancet. 1993;  342 1255-1262
    PubMedGoogle Scholar
  • 16 Anonymous . Stroke Prevention in Atrial Fibrillation Study. Final results.  Circulation. 1991;  84 527-539
    PubMedGoogle Scholar
  • 17 Ezekowitz M D, Bridgers S L, James K E. et al . Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators.  N Engl J Med. 1992;  327 1406-1412
    CrossrefPubMedGoogle Scholar
  • 18 ACTIVE Writing Group on behalf of the ACTIVE Investigators . Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W).  Lancet. 2006;  367 1903-1912
    CrossrefPubMedGoogle Scholar
  • 19 Nieuwlaat R, Capucci A, Camm A J. et al . Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation.  Eur Heart J. 2005;  26 2422-2434
    CrossrefPubMedGoogle Scholar
  • 20 Dentali F, Douketis J D, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease. A meta-analysis of randomised trials.  Arch Intern Med. 2007;  167 117-124
    CrossrefPubMedGoogle Scholar
  • 21 Lip G Y, Huber K, Andreotti F. et al . Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting.  Thromb Haemost. 2010;  103 13-28
    PubMedGoogle Scholar
  • 22 Rost S, Fregin A, Ivaskevicius V. et al . Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.  Nature. 2004;  427 537-541
    CrossrefPubMedGoogle Scholar
  • 23 Kirchheiner J, Ufer M, Walter E C. et al . Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers.  Pharmacogenetics. 2004;  14 19-26
    CrossrefPubMedGoogle Scholar
  • 24 Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.  Blood. 2000;  96 1816-1819
    PubMedGoogle Scholar
  • 25 Ezekowitz M D, Reilly P A, Nehmiz G. et al . Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).  Am J Cardiol. 2007;  100 1419-1426
    CrossrefPubMedGoogle Scholar
  • 26 Connolly S J, Ezekowitz M D, Yusuf S. et al . Dabigatran versus warfarin in patients with atrial fibrillation.  N Engl J Med. 2009;  361 1139-1151
    CrossrefPubMedGoogle Scholar
  • 27 The AMADEUS Investigators . Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.  Lancet. 2008;  371 315-321
    CrossrefPubMedGoogle Scholar
  • 28 ROCKET AF Study Investigators . Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.  Am Heart J. 2010;  159 340-347
    CrossrefPubMedGoogle Scholar
  • 29 Lopes R D, Alexander J H, Al-Khatib S M. et al . Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.  Am Heart J. 2010;  159 331-339
    CrossrefPubMedGoogle Scholar

Dr. med. Tobias Geisler

Medizinische Klinik III
Eberhard-Karls-Universität Tübingen

Otfried-Müller-Straße 10
72076 Tübingen

Email: tobias.geisler@email.de

      >